Neurodegenerative disorders, whether caused by genetic defects, trauma, or other insults, result in long term deficits that seriously compromise the quality of life. The mechanisms that lead to neurodegeneration are complex, but recurrent themes suggest different types of neurodegenerative disorders may share common mechanisms. During the previous grant period, we made significant progress in developing two ideas: 1) that NO (nitric oxide) could be a major contributor to neuron death during ischemia, and 2) that growth factors and second messenger systems could modify the sensitivity of neurons to NO and ischemia. It is becoming increasingly clear that NO may play a central role in a number of neurodegenerative diseases, including Huntington's Chorea, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. Signalling systems that minimize the damage caused by NO have the potential are potential therapeutic agents. This application focuses both on the mechanism of NO-toxicity and on neuroprotective mechanisms. It builds on several observations from the previous grant period. We want to determine signaling pathways controlled by growth factors are protective and which gene products make neurons more resistant to NO-toxicity. We are also interested in determining the toxic events that are controlled by NO that lead to cell death.
The specific aims of this grant are:
Specific Aim 1. To determine the roles of the ras/MAP kinase and the rac pathways in protection against NO toxicity.
Specific Aim 2 (a). To understand the toxic effects of cGMP on hippocampal neurons.
Specific Aim 2 (b). To determine the importance of a cascade of events, including the production of cGMP, the activation of cGMP-gated non-selective cation channels (cGGCC), and the activation of the cGMP-dependent protein kinase in the sensitivity of hippocampal neurons to NO-toxicity and ischemia.
Specific Aim 3. To isolate genes that encode proteins which confer resistance to NO toxicity by using an expression-cloning approach. Our long range goals are to understand the role of NO in ischemia and neurodegenerative disorders, to understand how growth factors and other signaling molecules can protect neurons from the toxic effects of NO, and to translate these discoveries into therapy.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (02))
Program Officer
Kitt, Cheryl A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Schools of Medicine
New York
United States
Zip Code
Castella, P; Wagner, J A; Caudy, M (1999) Regulation of hippocampal neuronal differentiation by the basic helix-loop-helix transcription factors HES-1 and MASH-1. J Neurosci Res 56:229-40
Lamoureux, P; Altun-Gultekin, Z F; Lin, C et al. (1997) Rac is required for growth cone function but not neurite assembly. J Cell Sci 110 ( Pt 5):635-41
Strom, A; Castella, P; Rockwood, J et al. (1997) Mediation of NGF signaling by post-translational inhibition of HES-1, a basic helix-loop-helix repressor of neuronal differentiation. Genes Dev 11:3168-81
Wagner, J A (1996) Is IL-6 both a cytokine and a neurotrophic factor? J Exp Med 183:2417-9
Altun-Gultekin, Z F; Wagner, J A (1996) Src, ras, and rac mediate the migratory response elicited by NGF and PMA in PC12 cells. J Neurosci Res 44:308-27
Boniece, I R; Wagner, J A (1995) NGF protects PC12 cells against ischemia by a mechanism that requires the N-kinase. J Neurosci Res 40:1-9
Endoh, M; Maiese, K; Wagner, J A (1994) Expression of the neural form of nitric oxide synthase by CA1 hippocampal neurons and other central nervous system neurons. Neuroscience 63:679-89
Endoh, M; Maiese, K; Wagner, J (1994) Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 651:92-100
Endoh, M; Maiese, K; Pulsinelli, W A et al. (1993) Reactive astrocytes express NADPH diaphorase in vivo after transient ischemia. Neurosci Lett 154:125-8